Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW3: NVA237 on Exercise Endurance in COPD
NCT01154127Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jun 2010; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01154127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154127.